News >

Immunotherapy Advances SCLC Treatment Landscape

Brandon Scalea
Published: Thursday, Dec 27, 2018

Christine Lee Hann, MD, PhD

Christine Lee Hann, MD, PhD

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer (SCLC) should be atezolizumab (Tecentriq) and chemotherapy, based on results from the IMpower133 trial, said Christine Lee Hann, MD, PhD.

In the cohort of 403 treatment-naïve patients, all patients received four 21-day cycles of carboplatin AUC 5 mg/mL/min intravenously (IV) on day 1 and 100 mg/m2 etoposide IV on days 1 through 3. Patients were also randomized 1:1 to receive either concurrent atezolizumab at 1200 mg IV on day 1 (n = 201) or placebo (n = 202) during the induction phase. Treatment was followed by maintenance therapy with atezolizumab or placebo, according to the previous random assignment, every 3 weeks until progressive disease or loss of clinical benefit.

Moreover, single-agent nivolumab (Opdivo) was granted an accelerated FDA approval in August 2018 for the treatment of patients with SCLC with disease progression following platinum-based chemotherapy and 1 other line of therapy, marking the first drug approval in this disease in nearly 20 years.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication